ICH Q1E Data Use in Re-Test Period Justification
In pharmaceutical manufacturing, the re-test period is a critical parameter for active pharmaceutical ingredients (APIs) and certain drug products. Regulatory authorities expect this period to be scientifically justified using robust stability data. This article walks you through how to use ICH Q1E guidelines to justify re-test periods, ensuring your submission aligns with global expectations. 💡…
Read More “ICH Q1E Data Use in Re-Test Period Justification” »